Modified immune cells target Tough-to-Treat kidney disease
NCT ID NCT07241468
Summary
This early-stage study is testing a new type of cell therapy called universal CAR-T cells (KN3601) in adults with severe autoimmune kidney diseases that have not responded to standard treatments. The main goals are to check if the treatment is safe and to see if it can help control the disease by targeting specific immune cells. Researchers will enroll about 36 participants to monitor for side effects and early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY IMMUNE NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.